{"filing":{"accession_number":"0001193125-26-408052","cik":"0001613780","ticker":"DBVTF","company_name":"DBV Technologies S.A.","form":"8-K","filing_date":"2026-09-29","report_date":"2026-09-29","primary_document":"d118963d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526408052/d118963d8k.htm"},"events":[{"id":35876,"run_id":33062,"accession_number":"0001193125-26-408052","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"DBV Technologies announced submission of a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch in children aged 4-7 years, supported by successful Phase 3 VITESSE trial results and with Priority Review requested. This is a material regulatory milestone for a late-stage biopharmaceutical company advancing toward commercialization, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It represents a significant operational/strategic advancement in the company's product development pipeline.","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-09-29","form":"8-K","submitted_at":null,"items":[{"id":40089,"accession_number":"0001193125-26-408052","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"DBV Technologies announced submission of a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch in children aged 4-7 years, supported by successful Phase 3 VITESSE trial results and with Priority Review requested. This is a material regulatory milestone for a late-stage biopharmaceutical company advancing toward commercialization, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It represents a significant operational/strategic advancement in the company's product development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:04:58.402139+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":40089,"accession_number":"0001193125-26-408052","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"DBV Technologies announced submission of a Biologics License Application (BLA) to the FDA for VIASKIN® Peanut Patch in children aged 4-7 years, supported by successful Phase 3 VITESSE trial results and with Priority Review requested. This is a material regulatory milestone for a late-stage biopharmaceutical company advancing toward commercialization, but does not fit the specific categories of earnings release, M\u0026A activity, or other named event types. It represents a significant operational/strategic advancement in the company's product development pipeline.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-30T10:04:58.402139+00:00","company_name":"DBV Technologies S.A.","ticker":"DBVTF","filing_date":"2026-09-29"}]}